Penumbra earnings date
Penumbra (0P8) Q3 2025 Earnings Report
DE:0P8 Q3 2025 EPS Results
- Actual EPS
- EUR 0.88
- Consensus EPS
- EUR 0.85
- Beat/Miss
- Beat by +EUR 0.04
- One Year Ago EPS
- EUR 0.77
DE:0P8 Q3 2025 Revenue Results
- Actual Revenue
- EUR 322.67M
- Expected Revenue
- EUR 310.18M
- Beat/Miss
- Beat by +EUR 12.49M
- YoY Revenue Growth
- +17.82%
Earnings Announcement Details
- Quarter
- Q3 2025
- Date
- 11/05/2025
- Time
- After Close
- Conference Call
- Wednesday, November 5, 2025
Penumbra's next earnings date is estimated for February 23, 2027, based on past reporting schedules.
Q3 2025 Earnings Call Audio
Q3 2025 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2025 Earnings Call Summary
The earnings call reflected a strong performance with significant revenue growth, particularly in the VTE and embolization segments, and positive developments in clinical trials, offset by some challenges in international markets and increased operational costs.
During Penumbra's third-quarter 2025 conference call, the company reported total revenue of $354.7 million, marking a 17.8% year-over-year growth on a reported basis and 16.9% in constant currency. U.S. revenue reached $275 million, a 21.5% increase compared to the previous year. Specifically, U.S. thrombectomy sales rose by 18.5% to $192 million, while the VTE franchise led corporate growth with a 34% rise. Meanwhile, U.S. embolization and access revenue soared by 29.2% to $83 million. International revenue was $79.7 million, reflecting a 6.6% year-over-year increase. The company's gross margin expanded by 130 basis points to 67.8%, and operating income stood at $48.8 million, or 13.8% of revenue. Penumbra's guidance for the year was raised to $1.375 billion to $1.380 billion in revenue, with anticipated U.S. thrombectomy growth of 20% to 21% for 2025. The company remains focused on expanding its market presence, particularly through innovative products like the Lightning Bolt 16 and Lightning Flash 3.0, which have received FDA clearance.
- Strong Revenue GrowthTotal revenue reached $354.7 million, showing a year-over-year growth of 17.8% on a reported basis and 16.9% in constant currency. U.S. revenue grew by 21.5% to $275 million.
- VTE Franchise Leading GrowthThe VTE franchise delivered a 34% year-over-year growth, driving overall corporate growth.
- Embolization and Access Revenue SurgeU.S. embolization and access revenue increased by 29.2% year-over-year to $83 million.
- Gross Margin ExpansionGross margin improved to 67.8%, up 130 basis points from the previous year, with expectations to reach over 70% by the end of 2026.
- Positive Feedback for STORM-PE TrialSTORM-PE trial results showed CAVT superior in reducing right heart strain in PE patients with a favorable safety profile, receiving positive feedback from the medical community.
- Raising Revenue GuidanceThe company raised its revenue guidance for the year to $1.375 billion to $1.380 billion.
DE:0P8 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 23, 2027 | 2026 (Q4) | 1.30- | 1.07 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | 1.090.97 | 0.88 | 10.31% (+0.09) | |
| Jul 30, 2026 | 2026 (Q2) | 1.060.80 | 0.78 | 2.33% (+0.02) | |
| May 06, 2026 | 2026 (Q1) | 0.940.75 | 0.76 | -1.20% (-0.01) | |
| Feb 25, 2026 | 2025 (Q4) | 1.011.07 | 0.88 | 21.65% (+0.19) | |
| Nov 05, 2025 | 2025 (Q3) | 0.850.88 | 0.77 | 14.12% (+0.11) | |
| Jul 29, 2025 | 2025 (Q2) | 0.750.78 | 0.58 | 34.38% (+0.20) | |
| Apr 23, 2025 | 2025 (Q1) | 0.610.76 | 0.37 | 102.44% (+0.38) | |
| Feb 18, 2025 | 2024 (Q4) | 0.820.88 | 0.69 | 27.63% (+0.19) | |
| Oct 30, 2024 | 2024 (Q3) | 0.620.77 | 0.61 | 26.87% (+0.16) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

